EUVIMEDEUVIMED entdecken
Crossref

In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC

Pousali Mitra, Akash Panja, Rashmi Pirthwar, Bat Chen R Lubin, Dror Tobi, Gary Gellerman

Bioorganic Chemistry · 2026-11 · 183 · 110607

DOI: 10.1016/j.bioorg.2026.110607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Pousali Mitra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Sciences, Ariel University, Ariel 4070000, Israel; Department of Molecular Biology Ariel University, Ariel 4070000, Israel. El…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Peptides. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Israel Ministry of Innovation Science & Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic antibodies represent clinically validated binding interfaces that remain largely unexplored as sources of targeting peptides. Here, we employed a structure-guided approach to extract and optimize an EGFR-binding motif from the anti-EGFR monoclonal antibody necitumumab and transformed it into a peptide-drug conjugate for targeted treatment of EGFR-overexpressed non-small-cell lung cancer (NSCLC). Although necitumumab is an FDA-approved therapeutic for EGFR-positive NSCLC, its clinical effectiveness is constrained by limited antitumor efficacy, inadequate penetration into solid tumors, the development of resistance, and clinically significant on-target toxicities. Like other monoclonal antibodies, necitumumab is a large protein biomolecule whose receptor-binding activity is mediated by a relatively small structural interface, providing an opportunity to re-engineer this functional region into a minimal peptide scaffold. We hypothesized that structure-guided extraction of antibody paratopes could provide a rational route for peptide ligand discovery, retaining receptor specificity while improving tumor penetration and eliminating Fc-driven toxicity. Using the resolved necitumumab Fab-EGFR co-crystal structure, we extracted the primary receptor-contact segment from the antibody paratope by implementing protein-protein interaction analysis and re-engineered it through systematic in silico mutation into an optimized peptide scaffold using MD and MM/GBSA combination protocol. A novel peptide scaffold PE3 (YIYYSFSQDYWP) was identified as the most advantageous carrier, showing favorable affinity toward EGFR (∆G = -66.12 kcal/mol) and subsequently validated to exhibit potent cellular uptake. To evaluate its therapeutic potential, PE3 was converted into a peptide-drug conjugate (PDC) through conjugation with Ahx-DA1, a metabolically stable analogue of dolastatin-10, yielding the conjugate PE3-DA1with IC50 0.05 ± 0.01 μM against H1975 NSCLC cell line. PE3-DA1 retained potent and selective antiproliferative activity against EGFR-positive cells. In the NSCLC xenograft model, PE3-DA1 induced complete tumor regression without evidence of off-target toxicity. This study demonstrates for the first time that a defined EGFR-binding interface within the necitumumab antibody can be reduced to an optimized peptide scaffold while preserving its targeting function and subsequently exploited as a PDC carrier to achieve selective antitumor activity against EGFR-overexpressing NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungAntineoplastic AgentsPeptidesAntibodies, MonoclonalHumansErbB ReceptorsAnimalsCell ProliferationDrug Screening Assays, AntitumorMiceStructure-Activity RelationshipCell Line, TumorMolecular StructureDose-Response Relationship, DrugAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Biomaterial designCADD, in silico engineeringDolastatin-10EGFRNSCLCPeptide drug conjugate

Substanzen

ErbB ReceptorsnecitumumabAntineoplastic AgentsPeptidesAntibodies, MonoclonalEGFR protein, humanAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Chemical Sciences, Ariel University, Ariel 4070000, Israel; Department of Molecular Biology Ariel University, Ariel 4070000, Israel. Electronic address: mitrap@ariel.ac.il.
  • Department of Chemical Sciences, Ariel University, Ariel 4070000, Israel. Electronic address: akash@ariel.ac.il.
  • Department of Molecular Biology Ariel University, Ariel 4070000, Israel. Electronic address: rashmi.pirthwar@msmail.ariel.ac.il.
  • Department of Chemical Engineering, Biotechnology and Materials, Ariel University, Ariel 4070000, Israel; Agriculture and Oenology Department, Eastern Regional R&D Center, Ariel 4070000, Israel.
  • Department of Molecular Biology Ariel University, Ariel 4070000, Israel. Electronic address: drorto@ariel.ac.il.
  • Department of Chemical Sciences, Ariel University, Ariel 4070000, Israel. Electronic address: garyg@ariel.ac.il.

Förderung

  • Israel Ministry of Innovation Science & Technology

Zitieren

APA

Mitra, P., Panja, A., Pirthwar, R., Lubin, B. C. R., Tobi, D., & Gellerman, G. (2026). In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC. Bioorganic Chemistry, 183, 110607. https://doi.org/10.1016/j.bioorg.2026.110607

Vancouver

Mitra P, Panja A, Pirthwar R, Lubin BCR, Tobi D, Gellerman G. In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC. Bioorganic Chemistry. 2026;183:110607. doi:10.1016/j.bioorg.2026.110607

BibTeX
@article{Mitra2026,
  author = {Mitra, Pousali and Panja, Akash and Pirthwar, Rashmi and Lubin, Bat Chen R and Tobi, Dror and Gellerman, Gary},
  title = {In silico miniaturization of the necitumumab EGFR-binding interface into a peptide scaffold for targeted therapy of EGFR-overexpressing NSCLC},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {183},
  pages = {110607},
  doi = {10.1016/j.bioorg.2026.110607}
}
Kostenlos starten →